Literature DB >> 1521907

pS2 protein and steroid hormone receptors in invasive breast carcinomas.

F C Koerner1, D E Goldberg, S M Edgerton, L H Schwartz.   

Abstract

We have used immunohistochemical and hormone-binding techniques to determine the presence of estrogen receptors, estrogen-receptor protein, progesterone receptors and pS2 protein in 97 invasive breast cancers. Our group of tumors displayed the same frequency of estrogen receptors and progesterone receptors as other comparable groups, but it contained more tumors containing pS2 protein. We also observed staining of morphologically normal cells in lobules adjacent to the tumors and in several fibroadenomas; both findings vary from some other reports. We attribute these variations to the use of a sensitive immunohistochemical method and choice of the lowest possible threshold to classify a tumor as pS2-positive. If we used a higher threshold, then about 95% of the tumors containing pS2 protein also contained estrogen receptor protein. Our results add further weight to the assertion that tumors containing pS2 protein also display estrogen receptors. The data also provide theoretical and indirect support to the clinical prediction that tumors containing pS2 protein are more likely to respond to hormonal therapy and may have a more indolent course than tumors lacking the molecule.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1521907     DOI: 10.1002/ijc.2910520205

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  A second trefoil protein, ITF/hP1.B, is transcribed in human breast cancer.

Authors:  B Theisinger; G Seitz; S Dooley; C Welter
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases.

Authors:  I Soubeyran; J Wafflart; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

3.  Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation.

Authors:  R D Whelan; B T Hill
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Prognostic evaluation of oestrogen-regulated protein immunoreactivity in ductal invasive (NOS) breast cancer.

Authors:  L Nakopoulou; A C Lazaris; D Baltas; I Giannopoulou; N Kavantzas; A Tzonou
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  pS2 and response to adjuvant hormone therapy in primary breast cancer.

Authors:  F Spyratos; C Andrieu; K Hacène; P Chambon; M C Rio
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

6.  Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.

Authors:  S Marsigliante; L Biscozzo; M Correale; A Paradiso; G Leo; I Abbate; C D Dragone; C Storelli
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

7.  Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

Authors:  J A Foekens; H Portengen; M P Look; W L van Putten; B Thirion; M Bontenbal; J G Klijn
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.